Concepedia

Craig Fancourt

CF

18

Publications

511

Citations

15

H-Index

1998

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

University of Florida

Institute of Cancer Research

The University of Texas MD Anderson Cancer Center

Craig Fancourt is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in engineering, signal processing, and pharmacology.

Top concepts

Publications per year

1998–2024

18

Publications

18

Phase I Trial of the Human Double Minute 2 Inhibitor MK-8242 in Patients With Advanced Solid Tumors

Andrew J. Wagner, Udai Banerji, Amit Mahipal et al. · Journal of Clinical Oncology · 2017 · 125 citations · Full text

A phase I trial of the human double minute 2 inhibitor (MK-8242) in patients with refractory/recurrent acute myelogenous leukemia (AML)

Farhad Ravandi, Ivana Gojo, Mrinal M. Patnaik et al. · Leukemia Research · 2016 · 53 citations · Full text

, , +8

Clinical Evaluation of <scp>MK</scp>‐2640: An Insulin Analog With Glucose‐Responsive Properties

Alexander W. Krug, Sandra A. G. Visser, Kuenhi Tsai et al. · Clinical Pharmacology & Therapeutics · 2018 · 39 citations

, , +15

The coherence function in blind source separation of convolutive mixtures of non-stationary signals

Craig Fancourt, Lucas C. Parra · 2002 · 31 citations

, , +17

A phase 1b study of the Akt-inhibitor MK-2206 in combination with weekly paclitaxel and trastuzumab in patients with advanced HER2-amplified solid tumor malignancies

A. Jo Chien, Alyson Cockerill, Craig Fancourt et al. · Breast Cancer Research and Treatment · 2016 · 31 citations

, , +7

Rows per page

1–5 of 18